SEC Comment Letter for INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Oct 14, 2022
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: Oct. 14, 2022 · CIK: 0001055726 · Accession: 0000000000-22-011338
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo October 14, 2022 Peter Kies Chief Financial Officer Inovio Pharmaceuticals, Inc. 660 W. Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 Re:Inovio Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2021 Filed March 1, 2022 File No. 1-14888 Dear Peter Kies: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
United States securities and exchange commission logo
October 14, 2022
Peter Kies
Chief Financial Officer
Inovio Pharmaceuticals, Inc.
660 W. Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
Re:Inovio Pharmaceuticals, Inc.
Form 10-K for the fiscal year ended December 31, 2021
Filed March 1, 2022
File No. 1-14888
Dear Peter Kies:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services